EyePoint, Inc. (NASDAQ: EYPT) Alert: Investors Encouraged to Contact KTMC Law Firm

RADNOR, Pa., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by EyePoint, Inc. (NASDAQ: EYPT) on behalf of investors who purchased or acquired EyePoint, Inc. securities and experienced significant financial losses.

GlobeNewsWire • an hour ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT).

PRNewsWire • Sep 3, 2026

EYEPOINT STOCKHOLDER ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In EyePoint (EYPT) To Contact Him Directly To Discuss Their Options

GlobeNewsWire • Sep 2, 2026

EYPT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving EyePoint Pharmaceuticals

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of EyePoint Pharmaceuticals (“EyePoint” or the “Company”) (NASDAQ: EYPT) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices.

GlobeNewsWire • Sep 3, 2026

EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting

WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the Company will participate at the following upcoming conferences:

GlobeNewsWire • Sep 2, 2026

EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

NEW YORK--(BUSINESS WIRE)---- $EYPT #ClassActionLawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of EyePoint Pharmaceuticals (“EyePoint” or the “Company”) (NASDAQ: EYPT) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On August 14, 2026, EyePoint released topline results in its Phase 3 LUGANO wet AMD trial for DURAVYU.

Business Wire • Sep 2, 2026

EYPT ALERT: Investigation Launched into EyePoint, Inc., Investors are Encouraged to Contact KTMC Law Firm

RADNOR, Pa., Aug. 28, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by EyePoint, Inc. (NASDAQ: EYPT) on behalf of investors who purchased or acquired EyePoint, Inc. securities and experienced significant financial losses.

PRNewsWire • Aug 28, 2026

EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $EYPT--EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law.

Business Wire • Aug 28, 2026

Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the Firm

RADNOR, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by EyePoint, Inc. (NASDAQ: EYPT) on behalf of investors who purchased or acquired EyePoint, Inc. securities and experienced significant financial losses.

GlobeNewsWire • Aug 27, 2026

EyePoint After Lugano: Primary Endpoint Miss, Asymmetric Risk-Reward

EyePoint is rated a speculative strong buy, with a revised fair value of $19 per share, despite increased regulatory risk after LUGANO's primary endpoint miss. LUGANO lowered estimated wet-AMD approval probability to 30%, but its strong durability results reinforced DURAVYU's competitive and commercial potential. LUGANO's primary endpoint miss appears largely driven by unusually unfavorable circumstances, supporting an estimated 70–75% chance that LUCIA meets its primary endpoint.

Seeking Alpha • Aug 27, 2026